# A Phase III Clinical Study of Valsartan Oral Solution for the Treatment of Hypertension in Children and Adolescents

Study · id `cardio:ct-nct06863987` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06863987](<https://clinicaltrials.gov/study/NCT06863987>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT06863987

Browse, organ or system: Blood vessels  
Browse, condition area: High blood pressure  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is enrolling by invitation. It plans to enroll 342 participants.

## Technical summary

Registry record NCT06863987. Allocation not applicable; double masking; primary purpose treatment. Start 2025-02-05 (actual); primary completion 2027-12 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; allocation not applicable; double masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 342 participants (planned count; ClinicalTrials.gov record NCT06863987, source copy `cardio:ctgov-nct06863987-2025-03-07`, retrieved 2026-10-26)
- Started: 2025-02-05 (actual) (ClinicalTrials.gov record NCT06863987, source copy `cardio:ctgov-nct06863987-2025-03-07`, retrieved 2026-10-26)
- Primary completion: 2027-12 (anticipated) (ClinicalTrials.gov record NCT06863987, source copy `cardio:ctgov-nct06863987-2025-03-07`, retrieved 2026-10-26)
- Completion: 2027-12 (anticipated) (ClinicalTrials.gov record NCT06863987, source copy `cardio:ctgov-nct06863987-2025-03-07`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT06863987, source copy `cardio:ctgov-nct06863987-2025-03-07`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "ENROLLING\_BY\_INVITATION" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06863987-2025-03-07`, retrieved 2026-10-26)

## The registry's words

- Brief title: A Phase III Clinical Study of Valsartan Oral Solution for the Treatment of Hypertension in Children and Adolescents
- Condition: Essential Hypertension
- Intervention (Drug): Valsartan Oral Solution
- Intervention (Drug): Placebo
- Lead sponsor: Shandong New Time Pharmaceutical Co., LTD
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Hypertension (high blood pressure) (`core:hypertension`)
- Registry intervention name matches this record once doses, forms and salt words are removed: Valsartan (`cardio:valsartan`)
- Registry intervention is a member of this class by a sourced record link: Angiotensin receptor blockers (ARBs) (`cardio:angiotensin-receptor-blockers-arbs`)

## Provenance

Content hash: deb0bd9c643188d6316d9513e55591c9c7f7a866a0a4035c2e6a25d46e5b5084
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
